Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
NCT06132503Phase 1Recruiting
- Sponsor
- Lantern Pharma
- Start
- Jan 2023
- Primary completion
- Nov 2028
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LP-284 in lymphoma and solid tumor, sponsored by Lantern Pharma. Primary endpoints: Safety and tolerability of escalating doses of LP-284 at 12 months, Maximum Tolerated Dose at 12 months and 2 more. Started Jan 2023; status: recruiting.
02
Drugs
LP-284
03
Conditions
lymphomasolid tumor
Beyond the preview
Go deeper on NCT06132503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132503.